Substantial proportions reported they would never discuss stopping HER2 directed treatment for metastatic breast cancer (44%) or a tyrosine-kinase inhibitor for oncogene-addicted lung cancer (69%) (Table 4). The gene discussed is ERBB2; the disease is lung carcinoma.